BChE inhib 
Welcome,         Profile    Billing    Logout  
 9 Companies  5 Products   5 Products   86 Diseases   20 Trials   2205 News 
27 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
rivastigmine transdermal / Generic mfg.
2020-005633-33: Prediction of ECT treatment response and reduction of Cognitive Side-effects using EEG and Rivastigmine

Not yet recruiting
4
100
Europe
Rivastigmine, Transdermal patch, Rivastigmine
University Medical Center Groningen, Netherlands Organization for Scientific Research
A depressive disorder, Depression, Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
RADIC, ChiCTR1900026313: Rivastigmine transdermal patch in Alzheimer's DIsease: a real-world evaluation of Caregiver burden

Recruiting
4
532
 
Rivastigmine transdermal patch ;Oral anti-dementia drugs
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University; Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, individual
Alzheimer's disease
 
 
PRECISER, NCT05768126: Prediction of ECT Treatment Response and Reduction of Cognitive Side-effects Using EEG and Rivastigmine

Recruiting
4
100
Europe
Rivastigmine Transdermal Product, Sham
UMC Utrecht, ZonMw: The Netherlands Organisation for Health Research and Development, St. Antonius Hospital, Tergooi Hospital
Depressive Disorder
12/25
01/26
2018-003219-23: CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson’s Disease)

Not yet recruiting
3
600
Europe
Rivastigmin Luye Transdermal Patches - 4.6mg/24h, Rivastigmine Luye Transdermal Patch- 9.5mg/24h, Rivastigmine transdermal system 13.3 mg/24 h, N/A, RIV-TDS 13.3 mg/24 h, Transdermal patch, Rivastigmin Luye Transdermal Patches - 4.6mg/24h, Rivastigmine Luye Transdermal Patch- 9.5mg/24h
University of Bristol, National Institute for Health Research, Health Assessment Technology Programme
This trial will investigate the effectiveness of Rivastigmine on prevention of falls in patients with Parkinson's disease, Parkinson's Disease is a condition in which the nervous system is damaged which leads to a loss of control of the muscles that control walking and balance., Diseases [C] - Nervous System Diseases [C10]
 
 
CHIEF PD, NCT04226248: CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease)

Active, not recruiting
3
600
Europe
Rivastigmine Transdermal System, Placebo Transdermal System
University of Bristol, Royal United Hospitals Bath NHS Foundation Trust
Parkinson Disease
05/24
02/25
NCT05883124: Rivastigmine Bioequivalence Trial With Multiple Applications of Transdermal Patches (9.5 mg/24 h)

Completed
1
38
Europe
Rivastigmine twice-weekly 9,5 mg/24 h, Exelon® 9.5 mg/24 h
SocraTec R&D GmbH
Bioequivalence
06/23
07/23
NCT05853341: Rivastigmine Bioequivalence Trial With Multiple Application of Transdermal Patches (13.3mg/24h)

Completed
1
48
Europe
RID-TDS 13.3 mg/24 h, Exelon® 13.3 mg/24 h
Luye Pharma Group Ltd., SocraTec R&D GmbH, SocraMetrics GmbH
Healthy
07/23
07/23
NCT04366518: Toward a Computationally-Informed, Personalized Treatment for Hallucinations

Recruiting
1
35
US
Rivastigmine Transdermal System, Scopolamine, Placebo Patch
Yale University, National Institute of Mental Health (NIMH)
Hallucinations, Auditory, Psychosis
08/32
08/32
ChiCTR-TRC-10001037: Efficacy of Rivastigmine Transdermal Patch in Dementia Patients who do not benefit from Oral Acetylcholinesterase Inhibitors (AChIs)

Completed
N/A
50
 
Exelon Patch (rivastigmine transdermal system)
NA; Level of the institution：, CUHK Neurology Research Fund
Dementia patients who are indicated for Acetylcholinesterase Inhibitors
 
 
rivastigmine / Generic mfg.
2005-004909-29: Satunnaistettu, kaksoissokkoutettu, lumekontrolloitu yhdessä keskuksessa toteutettu tutkimus rinnakkaisilla ryhmillä rivastigmiinin vaikutuksesta MS-tautiin liittyvän fatiikin aivomekanismeihin

Ongoing
4
32
Europe
Exelon 3,0 mg, Exelon 3,0 mg
Juhani Ruutiainen
Multippeliskleroosia sairastavat potilaat ja terveet vapaaehtoiset kontrollihenkilöt.
 
 
2006-004435-30: Protocol of study for the evaluation of the efficacy of rivastigmine on cognitive and behavioural disorders, following traumatic brain injury TBI in chronic patients.

Ongoing
4
12
Europe
EXELON 56CPS 1,5MG, EXELON 56CPS 1,5MG
FONDAZIONE SANTA LUCIA
Patients with cognitive and behavioural disorders following severe TBI and other severe acquired brain injury Glasgow Coma Scale GCS lower or equal 8
 
 
2017-000569-61: Comparison of therapeutic strategies with Cholinesterase Inhibitors: stop or still (SOS) trial

Not yet recruiting
4
1205
Europe
Donepezil, Galantamine, Rivastigmine, Donepezil, N06DA04, N06DA03, Coated tablet, Prolonged-release capsule, Capsule, ARICEPT, REMINYL, RIVASTIGMINE
CHU de Bordeaux, DGOS PHRC N 2016
Alzheimer disease Maladie d'Alzheimer, Diagnosis of probable or possible AD, defined according to the NINCDS-ARDRA criteria cMild to moderate stage, defined by a MMSE score above 15 at the time of pré-inclusion Nouveau cas de Maladie d'AlzheimerDiagnostic de MA probable ou possible définie selon les critères NINCDS-ARDRA, Diseases [C] - Nervous System Diseases [C10]
 
 
ChiCTR2100052254: Research on the Intervention Effect of Western Medicine on Preclinical AD: a Randomized Controlled Trial.

Recruiting
4
192
 
Take 971 Targeting Aβ Manno-oligosaccharide Diacid Capsules orally ;Take rivastigmine orally ;Take placebo group orally
Xuanwu Hospital, Capital Medical University; Xuanwu Hospital, Capital Medical University, The National Key Research and Development Project of China (grant number 2018YFC1315204)
Alzheimer's disease
 
 
ChiCTR2100048964: Real world study of kabalatin

Recruiting
4
10000
 
Rivastigmine Bitartrate Tablets
Beijing Yuanxin Technology Group Co., Ltd.; Wanquan Wante Pharmaceutical Jiangsu Co., Ltd., Wanquan Wante Pharmaceutical Jiangsu Co., Ltd.
Alzheimer's disease and dementia
 
 
NCT02670161: Quality Improvement and Practice Based Research in Neurology Using the EMR

Enrolling by invitation
4
3300
US
Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description), (too many characters to list in this field; see Intervention Description)
NorthShore University HealthSystem
Brain Tumors, Epilepsy, Migraine, Mild Cognitive Impairment, Concussion, Multiple Sclerosis, Neuropathy, Parkinson's, Restless Legs Syndrome, Stroke
12/25
12/26
NCT03454646: Comparison of Therapeutic Strategies With Cholinesterase Inhibitors (SOS TRIAL)

Not yet recruiting
4
1205
Europe
cholinesterase inhibitors (CI) (donepezil, galantamine or rivastigmine)
University Hospital, Bordeaux
Alzheimer Disease, Cholinesterase Inhibitors
04/27
09/27
RIVA-PSP, NCT02839642: Efficacy of RIVAstigmine on Motor, Cognitive and Behavioural Impairment in Progressive Supranuclear Palsy

Completed
3
106
Europe
Rivastigmine, Placebo
Assistance Publique Hopitaux De Marseille
Progressive Supranuclear Palsy (PSP)
06/22
11/22
DOPAD-3, NCT06702124: A Phase 3 Study of Rotigotine in Combination with Rivastigmine in Mild to Moderate Alzheimer's Disease

Recruiting
3
348
Europe
Rotigotine 4Mg/24Hrs Patch, Placebo
I.R.C.C.S. Fondazione Santa Lucia
Alzheimer Disease
07/25
04/26
NCT05564169 / 2021-002179-21: Masitinib in Patients With Mild to Moderate Alzheimer's Disease

Not yet recruiting
3
600
Europe
Placebo, Placebo Oral Tablet, Masitinib (4.5), AB1010, Standard of care
AB Science, AB Science, ABScience
Alzheimer Disease
12/26
12/26
2008-008896-32: Memory, Ageing, and the Cholinergic System a combined fMRI and PET study

Ongoing
2
40
Europe
N-[C-11]-Methylpiperidin-4-yl-acetate, C11-MP4A, Capsule, Solution for injection, Exelon
University of Cologne
Patients with mild cognitive impairment (MCI) (50-80 years), who are at greater risk of developing alzheimer's dementia will be recruited in the present study and will be compared to an age-matched group of healthy subjects (50-80 years).
 
 
2004-000507-17: Effectiveness of rivastigmine treatment in post-stroke patients with right brain damage and unilateral spatial neglect

Ongoing
2
20
Europe
Rivastigmine, NA,
FONDAZIONE SANTA LUCIA
Improvement of unilateral spatial neglect and functional status in right brain damaged patients
 
 
AR1005, NCT06537076: Safety and Efficacy of in Patients with Lewy Body Disease

Recruiting
2
60
RoW
AR1005, Scheduled for future release, Placebo, Rivastigmine 3 mg
Yonsei University, Samjin Pharmaceutical Co., Ltd., AriBio Co., Ltd.
Lewy Body Dementia
12/25
12/25
RIVA-AP, NCT06399679: Rivastigmine to Prevent Recurrence of Antimuscarinic Delirium

Recruiting
2
42
US
Rivastigmine, Placebo
Washington University School of Medicine, American Academy of Clinical Toxicology
Anticholinergic Toxicity
07/26
07/26
RIVA-AM, NCT06382649: Rivastigmine for Antimuscarinic Delirium

Not yet recruiting
2
42
US
Rivastigmine, Placebo
Washington University School of Medicine, American Academy of Clinical Toxicology
Anticholinergic Toxicity
07/26
07/26
NCT04962841: Nutraceuticals and Drug Treatment in Frail Older Adults

Recruiting
N/A
485
Europe
Nutraceuticals, empaglifozin, nebivolol, sertraline, rivastigmine, metformin, ramipril, amlodipine
University of Campania "Luigi Vanvitelli"
Frailty
07/21
04/23
TADF, NCT04732182: Telerehabilitation Alzheimer's Disease Feasibility

Recruiting
N/A
14
US
BrightGo cognitive training, Gamification for cognitive therapy, Standard of Care medication for early Alzheimer's Disease, Aricept 10 mg daily or Exelon 9.5 mg patch
Bright Cloud International Corp, National Institute on Aging (NIA), Rutgers, The State University of New Jersey
Alzheimer Disease, Healthy Aging
12/22
02/23
NCT06828289: Rivastigmine Mini-Tablet for Alzheimer's Disease

Not yet recruiting
N/A
1000
NA
Rivastigmine Mini-Tablet, Donepezil Hydrochloride
Peking University First Hospital
Alzheimer's Disease
12/26
12/26
VI-1121 / IEH Biopharma
No trials found
Zeyzelf (rivastigmine twice weekly) / Luye Group
No trials found
rivastigmine transdermal single-day patch (LY03011) / Luye Group
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
rivastigmine transdermal / Generic mfg.
2020-005633-33: Prediction of ECT treatment response and reduction of Cognitive Side-effects using EEG and Rivastigmine

Not yet recruiting
4
100
Europe
Rivastigmine, Transdermal patch, Rivastigmine
University Medical Center Groningen, Netherlands Organization for Scientific Research
A depressive disorder, Depression, Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
RADIC, ChiCTR1900026313: Rivastigmine transdermal patch in Alzheimer's DIsease: a real-world evaluation of Caregiver burden

Recruiting
4
532
 
Rivastigmine transdermal patch ;Oral anti-dementia drugs
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University; Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, individual
Alzheimer's disease
 
 
PRECISER, NCT05768126: Prediction of ECT Treatment Response and Reduction of Cognitive Side-effects Using EEG and Rivastigmine

Recruiting
4
100
Europe
Rivastigmine Transdermal Product, Sham
UMC Utrecht, ZonMw: The Netherlands Organisation for Health Research and Development, St. Antonius Hospital, Tergooi Hospital
Depressive Disorder
12/25
01/26
2018-003219-23: CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson’s Disease)

Not yet recruiting
3
600
Europe
Rivastigmin Luye Transdermal Patches - 4.6mg/24h, Rivastigmine Luye Transdermal Patch- 9.5mg/24h, Rivastigmine transdermal system 13.3 mg/24 h, N/A, RIV-TDS 13.3 mg/24 h, Transdermal patch, Rivastigmin Luye Transdermal Patches - 4.6mg/24h, Rivastigmine Luye Transdermal Patch- 9.5mg/24h
University of Bristol, National Institute for Health Research, Health Assessment Technology Programme
This trial will investigate the effectiveness of Rivastigmine on prevention of falls in patients with Parkinson's disease, Parkinson's Disease is a condition in which the nervous system is damaged which leads to a loss of control of the muscles that control walking and balance., Diseases [C] - Nervous System Diseases [C10]
 
 
CHIEF PD, NCT04226248: CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease)

Active, not recruiting
3
600
Europe
Rivastigmine Transdermal System, Placebo Transdermal System
University of Bristol, Royal United Hospitals Bath NHS Foundation Trust
Parkinson Disease
05/24
02/25
NCT05883124: Rivastigmine Bioequivalence Trial With Multiple Applications of Transdermal Patches (9.5 mg/24 h)

Completed
1
38
Europe
Rivastigmine twice-weekly 9,5 mg/24 h, Exelon® 9.5 mg/24 h
SocraTec R&D GmbH
Bioequivalence
06/23
07/23
NCT05853341: Rivastigmine Bioequivalence Trial With Multiple Application of Transdermal Patches (13.3mg/24h)

Completed
1
48
Europe
RID-TDS 13.3 mg/24 h, Exelon® 13.3 mg/24 h
Luye Pharma Group Ltd., SocraTec R&D GmbH, SocraMetrics GmbH
Healthy
07/23
07/23
NCT04366518: Toward a Computationally-Informed, Personalized Treatment for Hallucinations

Recruiting
1
35
US
Rivastigmine Transdermal System, Scopolamine, Placebo Patch
Yale University, National Institute of Mental Health (NIMH)
Hallucinations, Auditory, Psychosis
08/32
08/32
ChiCTR-TRC-10001037: Efficacy of Rivastigmine Transdermal Patch in Dementia Patients who do not benefit from Oral Acetylcholinesterase Inhibitors (AChIs)

Completed
N/A
50
 
Exelon Patch (rivastigmine transdermal system)
NA; Level of the institution：, CUHK Neurology Research Fund
Dementia patients who are indicated for Acetylcholinesterase Inhibitors
 
 
rivastigmine / Generic mfg.
2005-004909-29: Satunnaistettu, kaksoissokkoutettu, lumekontrolloitu yhdessä keskuksessa toteutettu tutkimus rinnakkaisilla ryhmillä rivastigmiinin vaikutuksesta MS-tautiin liittyvän fatiikin aivomekanismeihin

Ongoing
4
32
Europe
Exelon 3,0 mg, Exelon 3,0 mg
Juhani Ruutiainen
Multippeliskleroosia sairastavat potilaat ja terveet vapaaehtoiset kontrollihenkilöt.
 
 
2006-004435-30: Protocol of study for the evaluation of the efficacy of rivastigmine on cognitive and behavioural disorders, following traumatic brain injury TBI in chronic patients.

Ongoing
4
12
Europe
EXELON 56CPS 1,5MG, EXELON 56CPS 1,5MG
FONDAZIONE SANTA LUCIA
Patients with cognitive and behavioural disorders following severe TBI and other severe acquired brain injury Glasgow Coma Scale GCS lower or equal 8
 
 
2017-000569-61: Comparison of therapeutic strategies with Cholinesterase Inhibitors: stop or still (SOS) trial

Not yet recruiting
4
1205
Europe
Donepezil, Galantamine, Rivastigmine, Donepezil, N06DA04, N06DA03, Coated tablet, Prolonged-release capsule, Capsule, ARICEPT, REMINYL, RIVASTIGMINE
CHU de Bordeaux, DGOS PHRC N 2016
Alzheimer disease Maladie d'Alzheimer, Diagnosis of probable or possible AD, defined according to the NINCDS-ARDRA criteria cMild to moderate stage, defined by a MMSE score above 15 at the time of pré-inclusion Nouveau cas de Maladie d'AlzheimerDiagnostic de MA probable ou possible définie selon les critères NINCDS-ARDRA, Diseases [C] - Nervous System Diseases [C10]
 
 
ChiCTR2100052254: Research on the Intervention Effect of Western Medicine on Preclinical AD: a Randomized Controlled Trial.

Recruiting
4
192
 
Take 971 Targeting Aβ Manno-oligosaccharide Diacid Capsules orally ;Take rivastigmine orally ;Take placebo group orally
Xuanwu Hospital, Capital Medical University; Xuanwu Hospital, Capital Medical University, The National Key Research and Development Project of China (grant number 2018YFC1315204)
Alzheimer's disease
 
 
ChiCTR2100048964: Real world study of kabalatin

Recruiting
4
10000
 
Rivastigmine Bitartrate Tablets
Beijing Yuanxin Technology Group Co., Ltd.; Wanquan Wante Pharmaceutical Jiangsu Co., Ltd., Wanquan Wante Pharmaceutical Jiangsu Co., Ltd.
Alzheimer's disease and dementia
 
 
NCT02670161: Quality Improvement and Practice Based Research in Neurology Using the EMR

Enrolling by invitation
4
3300
US
Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description), (too many characters to list in this field; see Intervention Description)
NorthShore University HealthSystem
Brain Tumors, Epilepsy, Migraine, Mild Cognitive Impairment, Concussion, Multiple Sclerosis, Neuropathy, Parkinson's, Restless Legs Syndrome, Stroke
12/25
12/26
NCT03454646: Comparison of Therapeutic Strategies With Cholinesterase Inhibitors (SOS TRIAL)

Not yet recruiting
4
1205
Europe
cholinesterase inhibitors (CI) (donepezil, galantamine or rivastigmine)
University Hospital, Bordeaux
Alzheimer Disease, Cholinesterase Inhibitors
04/27
09/27
RIVA-PSP, NCT02839642: Efficacy of RIVAstigmine on Motor, Cognitive and Behavioural Impairment in Progressive Supranuclear Palsy

Completed
3
106
Europe
Rivastigmine, Placebo
Assistance Publique Hopitaux De Marseille
Progressive Supranuclear Palsy (PSP)
06/22
11/22
DOPAD-3, NCT06702124: A Phase 3 Study of Rotigotine in Combination with Rivastigmine in Mild to Moderate Alzheimer's Disease

Recruiting
3
348
Europe
Rotigotine 4Mg/24Hrs Patch, Placebo
I.R.C.C.S. Fondazione Santa Lucia
Alzheimer Disease
07/25
04/26
NCT05564169 / 2021-002179-21: Masitinib in Patients With Mild to Moderate Alzheimer's Disease

Not yet recruiting
3
600
Europe
Placebo, Placebo Oral Tablet, Masitinib (4.5), AB1010, Standard of care
AB Science, AB Science, ABScience
Alzheimer Disease
12/26
12/26
2008-008896-32: Memory, Ageing, and the Cholinergic System a combined fMRI and PET study

Ongoing
2
40
Europe
N-[C-11]-Methylpiperidin-4-yl-acetate, C11-MP4A, Capsule, Solution for injection, Exelon
University of Cologne
Patients with mild cognitive impairment (MCI) (50-80 years), who are at greater risk of developing alzheimer's dementia will be recruited in the present study and will be compared to an age-matched group of healthy subjects (50-80 years).
 
 
2004-000507-17: Effectiveness of rivastigmine treatment in post-stroke patients with right brain damage and unilateral spatial neglect

Ongoing
2
20
Europe
Rivastigmine, NA,
FONDAZIONE SANTA LUCIA
Improvement of unilateral spatial neglect and functional status in right brain damaged patients
 
 
AR1005, NCT06537076: Safety and Efficacy of in Patients with Lewy Body Disease

Recruiting
2
60
RoW
AR1005, Scheduled for future release, Placebo, Rivastigmine 3 mg
Yonsei University, Samjin Pharmaceutical Co., Ltd., AriBio Co., Ltd.
Lewy Body Dementia
12/25
12/25
RIVA-AP, NCT06399679: Rivastigmine to Prevent Recurrence of Antimuscarinic Delirium

Recruiting
2
42
US
Rivastigmine, Placebo
Washington University School of Medicine, American Academy of Clinical Toxicology
Anticholinergic Toxicity
07/26
07/26
RIVA-AM, NCT06382649: Rivastigmine for Antimuscarinic Delirium

Not yet recruiting
2
42
US
Rivastigmine, Placebo
Washington University School of Medicine, American Academy of Clinical Toxicology
Anticholinergic Toxicity
07/26
07/26
NCT04962841: Nutraceuticals and Drug Treatment in Frail Older Adults

Recruiting
N/A
485
Europe
Nutraceuticals, empaglifozin, nebivolol, sertraline, rivastigmine, metformin, ramipril, amlodipine
University of Campania "Luigi Vanvitelli"
Frailty
07/21
04/23
TADF, NCT04732182: Telerehabilitation Alzheimer's Disease Feasibility

Recruiting
N/A
14
US
BrightGo cognitive training, Gamification for cognitive therapy, Standard of Care medication for early Alzheimer's Disease, Aricept 10 mg daily or Exelon 9.5 mg patch
Bright Cloud International Corp, National Institute on Aging (NIA), Rutgers, The State University of New Jersey
Alzheimer Disease, Healthy Aging
12/22
02/23
NCT06828289: Rivastigmine Mini-Tablet for Alzheimer's Disease

Not yet recruiting
N/A
1000
NA
Rivastigmine Mini-Tablet, Donepezil Hydrochloride
Peking University First Hospital
Alzheimer's Disease
12/26
12/26
VI-1121 / IEH Biopharma
No trials found
Zeyzelf (rivastigmine twice weekly) / Luye Group
No trials found
rivastigmine transdermal single-day patch (LY03011) / Luye Group
No trials found

Download Options